• Sensorion posted a first-half net loss of €20.71 million, widening from €16.01 million a year earlier under IFRS.
• R&D expenses rose 9% to €16.4 million, while G&A costs climbed to €7.69 million from €4.14 million.
• Cash, cash equivalents and short-term deposits reached €88 million at June 30, up from €47.5 million at end-2025.
• ANSM authorized the Phase I/II HearConnex trial of SENS-601 in France; first patient dosing is expected by early 2027.
• Guidance calls for funding through end-2027, with SENS-601 IND submission in the U.S. and an Australia CTA by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260922291524) on September 23, 2026, and is solely responsible for the information contained therein.